Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock 
Instagram Outage Disrupts Thousands of U.S. Users 
DENVER, July 17, 2017 -- BioScrip, Inc. (NASDAQ:BIOS) ("BioScrip" or the "Company"), the largest independent national provider of infusion and home care management solutions, today announced that the Company will release its second quarter 2017 financial results on Tuesday, August 8, 2017 before the opening of U.S. financial markets.
Daniel E. Greenleaf, President and Chief Executive Officer, and Stephen Deitsch, Senior Vice President, Chief Financial Officer and Treasurer, will conduct a conference call as follows:
| Date | August 8, 2017 |
| Time | 9:00 a.m. EDT |
| Toll free (U.S.) | (888) 372-9592 |
| Webcast (live and replay) | www.bioscrip.com |
A replay of the conference call will be available for two weeks after the call's completion by dialing (855) 859-2056 (US) and entering conference call ID number 51901836.
About BioScrip
BioScrip, Inc. is the largest independent national provider of infusion and home care management solutions, with approximately 2,500 teammates and nearly 80 service locations across the U.S. BioScrip partners with physicians, hospital systems, payors, pharmaceutical manufacturers and skilled nursing facilities to provide patients access to post-acute care services. BioScrip operates with a commitment to bring customer-focused pharmacy and related healthcare infusion therapy services into the home or alternate-site setting. By collaborating with the full spectrum of healthcare professionals and the patient, BioScrip provides cost-effective care that is driven by clinical excellence, customer service, and values that promote positive outcomes and an enhanced quality of life for those it serves.
Investor Contacts Stephen Deitsch Chief Financial Officer & Treasurer T: (720) 697-5200 [email protected] David Clair ICR, Inc. T: (646) 277-1266 [email protected]
